Answers are grounded in this paper and cite their sources.
Demonstrates potent HMG-CoA reductase and cholesterol biosynthesis inhibition by novel substituted quinolines, indicating therapeutic potential comparable to compactin and mevinolin.
A series of substituted quinoline mevalonolactones were prepared and evaluated for their ability to inhibit the enzyme HMG-CoA reductase both in vitro and (cholesterol biosynthesis) in vivo. Since previous studies suggested that the 4-(4-fluorophenyl) and 2-(1-methylethyl) substituents afforded optimum potency, attention was focused on variations at position 6 of the quinoline ring. Biological evaluation of a small number of analogues bearing a variety of 6-substituents showed that modification at this position had little effect on potency. Several compounds (8b, 8e, and 11) were identified that showed comparable potency to compactin and mevinolin in both the in vitro and in vivo assays.
No takes yet. Share an insight, caveat, or question.
Sliskovic et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: